Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will speak at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. ET.

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will speak at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. ET. The event will be accessible via a webcast on the company's Investor Relations website.

Vericel focuses on advanced therapies for sports medicine and severe burn care, marketing MACI® for knee cartilage repair and Epicel® for severe burns treatment. The company also has rights to NexoBrid® for burn debridement, enhancing its product portfolio.

Argus Session date unavailable

-1.33% session move Open Argus

Details

News Market Reaction – VCEL

The recorded move for VCEL in the trading session of this news was -1.33%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42^nd Annual Health Care Conference on Wednesday, March 9th at 1:30 p.m. Eastern Time.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Vericel Corporation's stock symbol?

The stock symbol for Vericel Corporation is VCEL.

When will Nick Colangelo speak at the Cowen Health Care Conference?

Nick Colangelo will speak at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. ET.

How can I watch the webcast of Vericel's presentation?

The webcast of Vericel's presentation will be available on their Investor Relations website.

What products does Vericel Corporation market?

Vericel markets MACI® for knee cartilage repair and Epicel® for treatment of severe burns.

What is NexoBrid and its significance to Vericel?

NexoBrid is a registration-stage biological product for the debridement of severe thermal burns, for which Vericel holds exclusive North American rights.